Key facts
- This page summarizes Guiffre Christopherd T.'s Form 4 filing for Pear Therapeutics, Inc..
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 24 Jan 2023, 15:07.
Guiffre Christopherd T. - 20 Jan 2023 Form 4 Insider Report for Pear Therapeutics, Inc.
- Reporting relationship
- CFO, COO, Treas., & Asst. Sec.
- Issuer ticker
- N/A
- Reported as of
- 20 Jan 2023
- Net transaction value
- -$22,080
- SEC form
- 4
- Accepted by SEC
- 24 Jan 2023, 15:07:33 UTC
- Prior SEC filing
- 18 Jan 2023
- Next SEC filing
- 17 Feb 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Stacie S. Aarestad, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Filing notes and source
Key filing fact
Guiffre Christopherd T. filed Form 4 for Pear Therapeutics, Inc. on 24 Jan 2023.
Change
- Previous filing in this sequence was filed on 18 Jan 2023.
- Current net transaction value: -$22,080.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
PEARQ
transaction
Class A Common Stock
Sale
- Transaction value
- $22,080
- Shares
- -19,540
- Change %
- -39%
- Price
- $1.13*
- Shares after
- 29,960
- Date
- 20 Jan 2023
- Ownership
- Direct
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The sale reported on this Form 4 represents shares sold by the Reporting Person to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
Footnote F2
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $1.03 to $1.335, inclusive. The Reporting Person undertakes to provide to the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in this footnote of this Form 4.